About Ocera Therapeutics
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: OCRX
- Previous Close: $0.64
- 50 Day Moving Average: $1.38
- 200 Day Moving Average: $2.12
- 52-Week Range: $0.52 - $3.90
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.56
- P/E Growth: 0.00
- Market Cap: $14.81M
- Outstanding Shares: 23,143,000
- Beta: 2.17
- Net Margins: -23,816.53%
- Return on Equity: -116.62%
- Return on Assets: -73.71%
Companies Related to Ocera Therapeutics:
- Debt-to-Equity Ratio: 0.41%
- Current Ratio: 4.57%
- Quick Ratio: 4.57%
What is Ocera Therapeutics' stock symbol?
Ocera Therapeutics trades on the NASDAQ under the ticker symbol "OCRX."
Where is Ocera Therapeutics' stock going? Where will Ocera Therapeutics' stock price be in 2017?
6 brokers have issued 12 month target prices for Ocera Therapeutics' shares. Their forecasts range from $1.00 to $11.00. On average, they expect Ocera Therapeutics' stock price to reach $5.80 in the next twelve months.
When will Ocera Therapeutics announce their earnings?
Ocera Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Ocera Therapeutics stock?
Ocera Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Interwest Venture Management Co. (5.39%), Deerfield Management Co. (2.48%), Renaissance Technologies LLC (0.95%) and Vivo Capital LLC (0.66%). Company insiders that own Ocera Therapeutics stock include Gaurav Aggarwal, Linda S Grais, Michael Byrnes, Rajiv Patni, Stan Bukofzer and Wendall Wierenga.
Who bought Ocera Therapeutics stock? Who is buying Ocera Therapeutics stock?
Ocera Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Interwest Venture Management Co. and Renaissance Technologies LLC. Company insiders that have bought Ocera Therapeutics stock in the last two years include Gaurav Aggarwal, Linda S Grais, Michael Byrnes, Rajiv Patni, Stan Bukofzer and Wendall Wierenga.
How do I buy Ocera Therapeutics stock?
Shares of Ocera Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ocera Therapeutics stock cost?
One share of Ocera Therapeutics stock can currently be purchased for approximately $0.64.